Spectrum Pharmaceuticals, Inc. – NASDAQ:SPPI

Add to watchlist

Market closed

Open in 2 days

-14.17%

month

+32.48%

quarter

+33.52%

year

Market Cap	210.37M
Enterprise value	100.12M

P/E	-1.57
EV/Sales	2567.35
EV/EBITDA	-0.94
Price/Sales	3260.04
Price/Book	3.54
PEG ratio	-0.07
EPS	-0.36

Revenue	N/A
EBITDA	-61.88M
Income	-65.05M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-272128.21%
Oper. margin	-251041.03%
Gross margin	-7.69%
EBIT margin	-251041.03%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): Profit margin
Jun 2022	39K	-29.04M	-74474.36%
Sep 2022	0	-21.92M
Dec 2022	10.11M	-8.93M	-88.38%
Mar 2023	15.61M	-5.14M	-32.94%

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): Debt to assets
Jun 2022	79429000	45.98M	57.9%
Sep 2022	118929000	83.07M	69.85%
Dec 2022	103338000	75.45M	73.01%
Mar 2023	107675000	80.87M	75.11%

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): Cash Flow
Jun 2022	-23.44M	-34.90M	5.20M
Sep 2022	-17.90M	-1.76M	50.46M
Dec 2022	-25.33M	9.52M	-78K
Mar 2023	-21.44M	31.33M	2.11M

Spectrum Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Spectrum Pharmaceuticals
Employees

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): Employee count
Aug 2023	86
Sep 2023	86
Oct 2023	86
Nov 2023	86
Dec 2023	86
Jan 2024	86
Feb 2024	86
Mar 2024	86
Apr 2024	86
May 2024	86
Jun 2024	86
Jul 2024	86

Spectrum Pharmaceuticals
Hedge Funds Holdings Q2 2022

34.44% -11.67%

of SPPI is owned by hedge funds

76 -14

hedge funds hold SPPI stock

58.45M -12.95M

shares is hold by hedge funds

SPPI hedge funds holdings changes

Spectrum Pharmaceuticals
Insider Trading

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): Insider trades (number of shares)
Period	Buy	Sel
Jun 2022	0	30609
Nov 2022	50000	0
Jan 2023	0	267894
Feb 2023	0	67384
Mar 2023	0	92464
May 2023	0	32387

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	26 May 2023	BRENNAN NORA officer: CFO officer: CFO	Common Stock, $0.001 par value	32,387	$1.1	$35,496
Sale	15 Mar 2023	MCGAHAN KEITH M officer: Chief Le..	Common Stock, $0.001 par value	27,197	$0.8	$21,649
Sale	15 Mar 2023	RIGA THOMAS J director, officer..	Common Stock, $0.001 par value	31,381	$0.8	$24,979
Sale	14 Mar 2023	MCGAHAN KEITH M officer: Chief Le..	Common Stock, $0.001 par value	15,733	$0.82	$12,885
Sale	14 Mar 2023	RIGA THOMAS J director, officer..	Common Stock, $0.001 par value	18,153	$0.82	$14,867
Sale	23 Feb 2023	MCGAHAN KEITH M officer: Chief Le..	Common Stock, $0.001 par value	18,385	$0.77	$14,156
Sale	22 Feb 2023	MCGAHAN KEITH M officer: Chief Le..	Common Stock, $0.001 par value	11,990	$0.76	$9,124
Sale	22 Feb 2023	RIGA THOMAS J director, officer..	Common Stock, $0.001 par value	22,402	$0.77	$17,250
Sale	22 Feb 2023	RIGA THOMAS J director, officer..	Common Stock, $0.001 par value	14,607	$0.76	$11,116
Sale	31 Jan 2023	MCGAHAN KEITH M officer: Chief Le..	Common Stock, $0.001 par value	41,014	$0.62	$25,429

SPPI insider trading transactions

Spectrum Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Combination therapy using belinostat and pralatrexate to treat lymphoma Filling date: 14 Jun 2016 Issue date: 13 Sep 2022	14 Jun 2016	13 Sep 2022
Application	Application Methods of Treatment Using G-CSF Protein Complex Filling date: 28 Jan 2022 Issue date: 19 May 2022	28 Jan 2022	19 May 2022
Grant	Grant Utility: Methods of treatment using G-CSF protein complex Filling date: 31 May 2019 Issue date: 8 Mar 2022	31 May 2019	8 Mar 2022
Application	Application KITS AND METHODS FOR TREATING CANCERS Filling date: 12 Sep 2019 Issue date: 10 Feb 2022	12 Sep 2019	10 Feb 2022
Application	Application METHODS OF TREATING CHEMOTHERAPY INDUCED NEUTROPENIA USING FIXED DOSES OF G-CSF PROTEIN COMPLEX Filling date: 13 Jul 2021 Issue date: 20 Jan 2022	13 Jul 2021	20 Jan 2022
Application	Application NOVEL QUINAZOLINE EGFR INHIBITORS Filling date: 20 Sep 2019 Issue date: 18 Nov 2021	20 Sep 2019	18 Nov 2021
Application	Application POZIOTINIB COMBINATIONS WITH AN ANTI-HER1, HER2 OR HER4 ANTIBODY AND METHODS OF USE THEREOF Filling date: 25 Jun 2019 Issue date: 26 Aug 2021	25 Jun 2019	26 Aug 2021
Application	Application COMBINATION OF POZIOTINIB WITH CYTOTOXIC AGENT AND/OR OTHER MOLECULARLY TARGETED AGENT AND USE THEREOF Filling date: 25 Jun 2019 Issue date: 20 May 2021	25 Jun 2019	20 May 2021
Application	Application NOVEL METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX Filling date: 18 Aug 2020 Issue date: 14 Jan 2021	18 Aug 2020	14 Jan 2021
Application	Application INHIBITORS OF MUTANT FAMILY TYROSINE-KINASES Filling date: 18 Oct 2018 Issue date: 20 Aug 2020	18 Oct 2018	20 Aug 2020

SPPI patents

Spectrum Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q4 2022 22 Mar 2023	Q4 2022 Earnings Call Transcript
Q3 2022 10 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 11 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 12 May 2022	Q1 2022 Earnings Call Transcript

SPPI earnings call transcripts

Spectrum Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Thomas J. Riga (1975) Pres, Chief Executive Officer & Director	50	$1,030,000
Mr. Kurt A. Gustafson (1968) Executive Vice President & Chief Financial Officer	57	$953,390
Dr. Francois J. Lebel FRCPC, M.D. (1952) Executive Vice President & Chief Medical Officer	73	$926,760
Mr. Keith M. McGahan J.D., L.L.M. (1976) Executive Vice President, Chief Legal Officer & Corporation Sec.	49	$842,190

Spectrum Pharmaceuticals
Latest News

Wednesday, 2 October 2024
14:18	Qylur Awarded SBIR Phase II Contract for Tactical AI Spectrum Classifier Systems (TASCS)	globenewswire.com
14:18	Qylur Awarded SBIR Phase II Contract for a Tactical AI Spectrum Classifier Systems (TASCS)	globenewswire.com
Monday, 19 August 2024
08:48	NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387	proactiveinvestors.com
Thursday, 27 June 2024
07:10	STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines	globenewswire.com
Tuesday, 25 June 2024
05:00	Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033	businesswire.com
Thursday, 23 May 2024
07:00	Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference	globenewswire.com
Thursday, 2 May 2024
07:00	Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024	globenewswire.com
Tuesday, 28 November 2023
09:19	NanoViricides completes Phase 1a/1b human clinical trial for its broad-spectrum antiviral drug	Proactive Investors
Monday, 21 August 2023
08:16	NanoViricides reports progress in Phase 1a/1b human clinical trial of NV-CoV-2 broad-spectrum antiviral drug	Proactive Investors
Thursday, 22 June 2023
19:46	Spectrum's Rolvedon A Differentiator In A $3B/Yr Market	Seeking Alpha
Tuesday, 9 May 2023
09:56	Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Monday, 8 May 2023
15:18	7 Hot Penny Stocks Under $1.10 To Watch This Week	PennyStocks
Friday, 5 May 2023
13:09	Best Penny Stocks To Buy? 4 Under $1.10 To Watch Now	PennyStocks
Tuesday, 25 April 2023
11:51	Spectrum Pharmaceuticals stock pops after Assertio acquires it at a premium	Proactive Investors
08:27	Why Is Spectrum Pharmaceuticals (SPPI) Stock Up 35% Today?	InvestorPlace
Monday, 3 April 2023
22:49	10 Best-Performing Penny Stocks in the Health Care Sector	24/7 Wall Street
Wednesday, 22 March 2023
13:07	Spectrum Pharmaceuticals, Inc. (SPPI) Q4 2022 Earnings Call Transcript	Seeking Alpha
10:44	Spectrum Pharmaceuticals (SPPI) Reports Q4 Loss, Tops Revenue Estimates	Zacks Investment Research
Friday, 17 March 2023
07:00	Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update	Business Wire
Friday, 10 February 2023
06:00	How to Take Profits With Penny Stocks	PennyStocks
Thursday, 9 February 2023
08:28	10 Top Penny Stocks Under $1 To Watch For February 2023	PennyStocks
Tuesday, 31 January 2023
09:30	7 Top Penny Stocks To Watch With Big News This Week	PennyStocks
Thursday, 26 January 2023
18:06	The 3 Best Biotech Stocks Under $1 to Buy for January	InvestorPlace
Monday, 28 November 2022
13:32	Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA	Zacks Investment Research
Thursday, 10 November 2022
21:40	Spectrum Pharmaceuticals, Inc. (SPPI) Q3 2022 Earnings Call Transcript	Seeking Alpha
Monday, 24 October 2022
11:23	3 Hot Penny Stocks To Watch With The Stock Market Down Today	PennyStocks
Monday, 26 September 2022
13:32	Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug	Zacks Investment Research
Friday, 23 September 2022
08:45	Spectrum's stock is down after FDA committee voted against cancer drug	Market Watch
Monday, 19 September 2022
15:30	FDA advisory committee to review three cancer drugs this week	Market Watch
Monday, 12 September 2022
13:22	What Is Going on With Spectrum Pharmaceuticals (SPPI) Stock Today?	InvestorPlace

Ideas & Opinions

Seeking Alpha 24 Jul 2023

Buy Spectrum Pharmaceuticals For Exposure To Assertio Holdings
Seeking Alpha 22 Jun 2023

Spectrum's Rolvedon A Differentiator In A $3B/Yr Market
Seeking Alpha 20 Jun 2023

Assertio: Cheap And Growing Disruptor Of Pharma's Antiquated Sales Model
Seeking Alpha 4 May 2023

Assertio Holdings: A Little More Risk, A Lot Higher Reward
Seeking Alpha 14 Sep 2022

Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
Seeking Alpha 12 Aug 2021

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity
Seeking Alpha 1 Aug 2021

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space
Seeking Alpha 29 Jul 2021

Spectrum's Big Approval: Any Day Now
Seeking Alpha 2 Jun 2021

ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
Seeking Alpha 14 May 2021

Spectrum Pharmaceuticals: Rolontis Korean Facility Inspection Presents Opportunity

Frequently Asked Questions (FAQ)

When is Spectrum Pharmaceuticals's next earnings date?

Unfortunately, Spectrum Pharmaceuticals's (SPPI) next earnings date is currently unknown.
Does Spectrum Pharmaceuticals pay dividends?

No, Spectrum Pharmaceuticals does not pay dividends.
How much money does Spectrum Pharmaceuticals make?

Spectrum Pharmaceuticals has a market capitalization of 210.37M.
What is Spectrum Pharmaceuticals's stock symbol?

Spectrum Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "SPPI".
What is Spectrum Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Spectrum Pharmaceuticals?

Shares of Spectrum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Spectrum Pharmaceuticals's key executives?
Spectrum Pharmaceuticals's management team includes the following people:
- Mr. Thomas J. Riga Pres, Chief Executive Officer & Director(age: 50, pay: $1,030,000)
- Mr. Kurt A. Gustafson Executive Vice President & Chief Financial Officer(age: 57, pay: $953,390)
- Dr. Francois J. Lebel FRCPC, M.D. Executive Vice President & Chief Medical Officer(age: 73, pay: $926,760)
- Mr. Keith M. McGahan J.D., L.L.M. Executive Vice President, Chief Legal Officer & Corporation Sec.(age: 49, pay: $842,190)
How many employees does Spectrum Pharmaceuticals have?

As Jul 2024, Spectrum Pharmaceuticals employs 86 workers.
When Spectrum Pharmaceuticals went public?

Spectrum Pharmaceuticals, Inc. is publicly traded company for more then 29 years since IPO on 26 Sep 1996.
What is Spectrum Pharmaceuticals's official website?

The official website for Spectrum Pharmaceuticals is sppirx.com.
Where are Spectrum Pharmaceuticals's headquarters?

Spectrum Pharmaceuticals is headquartered at Pilot House – Lewis Wharf, Boston, MA.
How can i contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals's mailing address is Pilot House – Lewis Wharf, Boston, MA and company can be reached via phone at +61 75863900.

Spectrum Pharmaceuticals, Inc.

sppirx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

+61 75863900

Pilot House – Lewis Wharf
Boston, MA 02110

CIK: 0000831547
ISIN: US84763A1088
CUSIP: 84763A108